We anticipate increasing Shire’s (SHP) fair value estimate by about 5% following its agreement to acquire NPS Pharmaceuticals for $5.2 billion (£3.4 billion) in cash (or $46 per share). Our fair value estimate for the UK-listed Shire shares is £47.41.
We think the NPS deal reinforces Shire's narrow economic moat, otherwise known as its moderately sustainable competitive advantage, as it will add new drugs to Shire’s growing rare disease portfolio and leverage its gastrointestinal sales force. However, we're cautious about the acquisition's overall value creation, since the company is paying a high price for NPS, whose two key drugs Gattex (known as Revestive outside the US) and Natpara (Natpar) are attractive rare disease assets, but are still commercially unproven.
The $46-a-share offer represents a 10% premium to NPS’s last closing price and is 51% higher than its Dec. 16 price, when rumours of a potential Shire acquisition began to circulate in the media. The deal has been approved by both companies’ boards and is expected to be accretive to Shire’s non-GAAP EPS starting in 2016.
Read the analyst report on Shire here. Morningstar Equity Research is available to Premium members; get instant access when you take a free 14-day trial.
SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk
To view this article, become a Morningstar Basic member.
Register For Free
The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.